Sandoz CEO Saynor Talks Spinoff, Leadership And Place Among Peers
Firm Is Positioned As Last Pure Generics Player Among An Evolving Industry Big Three
In the first part of an exclusive three-part interview, Sandoz CEO Richard Saynor talks to Generics Bulletin about the firm’s upcoming separation from parent company Novartis, as well as outlining its unique position as a pure generics and biosimilars company among an evolving peer group of off-patent industry leaders.
